Prospective evaluation of early virological response associated with 40 kDa peginterferon alfa-2A (PEGASYS®) plus ribavirin therapy from a phase III, ranodmized, double-blind study examining the effects of treatment duration and ribavirin dosing: Stephanos J Hadziyannis, Hippokration General Hospital, Athens Greece; Hugo Cheinquer, Univ Fed do Rio Grande do Sul, Porto Alegre RS Brazil; Timothy Morgan, VA Medical Center, Long Beach, CA; Moises Diago, Hospital General de Valencia, Valencia Spain; Donald M Jensen, Rush-Presbyterian-St Luke's Hospital, Chicago, IL; Hoel Sette, Instituto de Infectologia Emilio Ribas, Sao Paulo Brazil; Giuliano Ramadori, Universitatsklinik Gottingen, Gottingen Germany; Henry C Bodenheimer Jr., Mount Sinai Hospital School of Medicine, New York, NY; Jean-Pierre Zarski, CHU de Grenoble, Hopital de la Tronche, Grenoble France; Shou-Dong Lee, Taipei Veterans General Hospital, Taipei Taiwan; Philipa Roberts, Andrew M Ackrill, Roche Products Ltd, Welwyn Garden City Uk